European
Commission issues fine in ‘pay for delay’ pharma investigation after a 9 year
probe
The
European Commission has fined Teva Pharmaceutical Industries Ltd and Cephalon
Inc EUR 60.5 million for entering into an unlawful patent settlement, in breach
of Article 101 of the TFEU.
The
Commission found that Teva agreed to delay for several years the market entry
of a cheaper generic version of Cephalon's drug for sleep disorders, modafinil,
after expiry of Cephalon's patents.
Teva
received cash payments and other side-deals, including a distribution agreement,
a licence on Teva modafinil patents, raw materials from Teva, and access to valuable
clinical data.
This
is the fourth "pay-for-delay" decision that the Commission has
adopted.
This
one is striking because of the form taken by the payments and value transfers.
https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2220
No comments:
Post a Comment